Evista · DIN 02239028 · 60 mg · tablet
Limited Use, Reason for Use code 373 required; Health Canada lists this DIN as Cancelled post market since 2026-01-30 — choose a marketed DIN from the same-category list.Discontinued January 30, 2026 · checked November 17, 2026
StatusLimited Use, Reason for Use code 373 required; Health Canada lists this DIN as Cancelled post market since 2026-01-30 — choose a marketed DIN from the same-category list.
Write on scriptReason for Use code 373 (criteria below); Health Canada lists this DIN as Cancelled post market since 2026-01-30 — choose a marketed DIN from the same-category list.
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 373
Coverage limit:
For the treatment of osteoporosis in postmenopausal women who have:
Reason for Use code 373
Failed or, experienced intractable side effects, or have a contraindication to, alendronate OR risedronate.
Coverage limit:
Failure is defined as: continued loss of bone mineral density (loss of more than 3%) after two years of therapy; or a new osteoporosis related fracture after one year of therapy.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Evista · DIN 02239028
Manufacturer: Eli Lilly Canada Inc.; listing date 2000-11-30
Health Canada: Cancelled post market since 2026-01-30 · brand EVISTA · ATC G03XC01 RALOXIFENE · form Tablet · route Oral · ingredients RALOXIFENE HYDROCHLORIDE 60 MG · company Eli lilly canada inc · schedule Prescription
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02239028)
Source record
DIN 02239028: Evista
Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y
Item: 920000323; group id 951; item number 2258; lccId 00133; manufacturer id LIL
Source form: Tab; strength: 60mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $2.3757; ministry $0.5134
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02239028
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62480
Interchangeable products
Act Raloxifene · DIN 02358840 · $0.5134
Apo-Raloxifene · DIN 02279215 · $0.5134
Jamp Raloxifene · DIN 02540681 · $0.5134
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since January 30, 2026 — choose a marketed DIN from the same-category list.